Stock Report: AMAG Pharmaceuticals Inc. (AMAG) Report Updated: May 20, 2013 | Print This Page

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company's principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). It sells Feraheme primarily to authorized wholesalers and specialty distributors. The company also has marketing approval for Feraheme in Canada. In addition, it is pursuing marketing applications in the European Union and Switzerland for Feraheme for the treatment of IDA in CKD patients. Further, the company provides GastroMARK, an oral contrast agent for delineating the bowel in magnetic resonance imaging in the United States, as well as internationally under the Lumirem name. The company has a license, development, and commercialization agreement with Takeda to develop and commercialize Feraheme. AMAG Pharmaceuticals, Inc. was founded in 1981 and is based in Lexington, Massachusetts.